The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's ...
Friday’s jobs report could bolster the view that the American economy is holding steady, but an oil price shock could ...
The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...
Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.
Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...
The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., ...
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...
The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...